


---

# Canada


## Treatment at diagnosis by country

### Global enrolment of Prospective patients


Region	n	%
Europe	29167	56
Asia	14988	28.8
North America	1618	3.1
Latin America	4247	8.2
Rest of World	2061	4
Total	52081	100




## Treatment at diagnosis by country



## Treatment at diagnosis by region



## Treatment at diagnosis by cohort



## Baseline characteristics

		Canada N=(889)	World N=(52081)
Sex	Female, n (%)	423 (47.6)	23015 (44.2)
Age at Diagnosis (Years)	mean (sd)	72.9 (11.4)	69.7 (11.5)
Age Group	<65, n (%)	194 (21.8)	15716 (30.2)
	65-74, n (%)	262 (29.5)	16956 (32.6)
	>=75, n (%)	433 (48.7)	19409 (37.3)
BMI (kg/m <sup>2</sup> )	mean (sd)	29.5 (7.0)	27.8 (5.7)
Pulse (bpm)	mean (sd)	96.1 (30.6)	90.4 (26.7)
Systolic BP (mm Hg)	mean (sd)	131.6 (21.5)	133.5 (19.8)
Diastolic BP (mm Hg)	mean (sd)	77.6 (14.4)	79.7 (12.9)
Congestive heart failure	n (%)	142 (16.0)	10405 (20.0)
Coronary artery disease	n (%)	204 (22.9)	11251 (21.6)
Acute coronary syndrome	n (%)	123 (13.9)	4914 (9.5)
Carotid Occlusive Disease	n (%)	27 (3.1)	1546 (3.0)
Cirrhosis	n (%)	4 (0.5)	296 (0.6)

## Baseline characteristics

		<b>Canada N=(889)</b>	<b>World N=(52081)</b>
Diabetes	n (%)	233 (26.2)	11550 (22.2)
History of Bleeding	n (%)	54 (6.2)	1320 (2.5)
Hypercholesterolaemia	n (%)	519 (59.3)	20975 (41.6)
PE or DVT	n (%)	32 (3.6)	1356 (2.6)
Stroke/TIA	n (%)	124 (13.9)	5961 (11.4)
Treatment Sector	In the private sector, n (%)	7 (1.0)	12547 (28.5)
	In the public sector, n (%)	702 (99.0)	31431 (71.5)

## Baseline characteristics

		<b>Canada N=(889)</b>	<b>World N=( 52081)</b>
CHADS2 Score	mean (sd)	2.0 (1.2)	1.9 (1.1)
CHA2DS2-VASc Score	mean (sd)	3.5 (1.6)	3.2 (1.6)
HAS BLED Score	mean (sd)	1.7 (0.9)	1.4 (0.9)



## Baseline characteristics

		Canada N=(889)	World N=(52081)
Systemic Embolization	n (%)	8 (0.9)	336 (0.6)
Type of AF Diagnosed	New, n (%)	564 (63.4)	23366 (44.9)
	Paroxysmal, n (%)	238 (26.8)	14313 (27.5)
	Permanent, n (%)	27 (3.0)	6639 (12.7)
Care Setting Speciality at Diagnosis	Persistent, n (%)	60 (6.7)	7761 (14.9)
	Cardiology, n (%)	567 (63.8)	34219 (65.7)
	Geriatrics, n (%)	0 (0.0)	202 (0.4)
	Internal Medicine, n (%)	166 (18.7)	9372 (18.0)
	Neurology, n (%)	5 (0.6)	876 (1.7)
	Primary Care/General Practice, n (%)	151 (17.0)	7410 (14.2)


# Main reason anticoagulant not used for patients with $CHA_2DS_2-VASc \geq 2$ .

	Cohort 1&2	
	Canada	World
	(N=83) n %	(N=4137) n %
Patients with $CHA_2DS_2-VASc \geq 2$ and no AC treatment at diagnosis		
Alcohol abuse	1 (1.2)	20 (0.5)
Already taking anti-platelet drugs for other medical condition	4 (4.8)	228 (5.5)
Patient refusal	3 (3.6)	336 (8.1)
Previous bleeding event	3 (3.6)	63 (1.5)
Taking medication contraindicated or cautioned for use with VKA or AC		19 (0.5)
Other	41 (49.4)	505 (12.2)
Unknown	13 (15.7)	889 (21.5)
Physician's choice	18 (21.7)	2077 (50.2)
Physician's choice - Bleeding risk	4 (4.8)	263 (6.4)
Physician's choice - Concern over patient compliance	1 (1.2)	182 (4.4)
Physician's choice - Guideline recommendation	2 (2.4)	105 (2.5)
Physician's choice - Fall risk	3 (3.6)	197 (4.8)
Physician's choice - Low risk of stroke	2 (2.4)	326 (7.9)
Physician's choice - Other	6 (7.2)	1004 (24.3)
Total	83 (100.0)	4137 (100.0)


# Main reason anticoagulant not used for patients with $\text{CHA}_2\text{DS}_2\text{-VASc} \geq 2$ .

	Cohort 3&4&5	
	Canada	World
	(N=132) n %	(N=6117) n %
Patients with $\text{CHA}_2\text{DS}_2\text{-VASc} \geq 2$ and no AC treatment at diagnosis		
Alcohol abuse		32 (0.5)
Already taking anti-platelet drugs for other medical condition	4 (3.0)	422 (6.9)
Patient refusal	9 (6.8)	645 (10.5)
Previous bleeding event	2 (1.5)	151 (2.5)
Taking medication contraindicated or cautioned for use with VKA or AC	3 (2.3)	63 (1.0)
Other	63 (47.7)	1326 (21.7)
Unknown	21 (15.9)	1597 (26.1)
Physician's choice	30 (22.7)	1881 (30.8)
Physician's choice - Bleeding risk	7 (5.3)	611 (10.0)
Physician's choice - Concern over patient compliance	1 (0.8)	248 (4.1)
Physician's choice - Guideline recommendation	8 (6.1)	189 (3.1)
Physician's choice - Fall risk	2 (1.5)	205 (3.4)
Physician's choice - Low risk of stroke	12 (9.1)	628 (10.3)
Total	132 (100.0)	6117 (100.0)


## Stroke risk profile: CHADS<sub>2</sub>



## Stroke risk profile: CHA<sub>2</sub>DS<sub>2</sub> VASc



## Stroke risk profile: HAS BLED



## Treatment at diagnosis by CHA<sub>2</sub>DS<sub>2</sub>-VASc score - Canada


CHA <sub>2</sub> DS <sub>2</sub> -VASc		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total
		n	n	n	n	n	n	n
Canada	Unknown	10	4	2	4	4	1	25
	0	3	3	2	2	2	0	12
	1	7	21	8	25	15	0	76
	2	19	47	13	43	20	5	147
	3	61	54	20	41	19	1	196
	4	69	65	20	44	20	3	221
	5	44	34	8	21	14	5	126
	6-9	33	24	3	14	12	0	86

# Treatment at diagnosis by CHA<sub>2</sub>DS<sub>2</sub>-VASc score - World


CHA <sub>2</sub> DS <sub>2</sub> -VASc		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total
		n	n	n	n	n	n	n
World	Unknown	461	227	62	286	330	14	1380
	0	325	221	111	302	443	16	1418
	1	1830	1097	479	1545	1196	66	6213
	2	3835	1960	806	2154	1261	125	10141
	3	4969	2625	817	2345	1275	164	12195
	4	4711	2352	772	2043	1028	168	11074
	5	2458	1169	375	1224	449	98	5773
	6-9	1616	831	234	872	261	73	3887



## Treatment at diagnosis



## Treatment at diagnosis




## Treatment at diagnosis by HAS BLED score - Canada

HASBLED		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total	
		n	n	n	n	n	n	N	n
Canada	Unknown	103	69	30	58	46	5	311	311
	0	11	23	4	0	9	1	48	48
	1	36	88	21	25	27	4	201	201
	2	60	62	18	76	17	3	236	236
	3	29	9	3	32	7	1	81	81
	4-9	7	1	0	3	0	1	12	12


# Treatment at diagnosis by HAS BLED score - World

HASBLED		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total
		n	n	n	n	n	n	n
World	Unknown	5750	2456	843	3271	2060	147	14527
	0	2144	1242	611	0	1394	96	5487
	1	6650	3866	1303	2302	1779	254	16154
	2	4165	2225	689	3689	763	163	11694
	3	1258	599	191	1250	219	53	3570
	4-9	238	94	19	259	28	11	649

## Treatment at diagnosis



## Treatment at diagnosis



## INR values and time in therapeutic range

Variable	Statistics	Canada (N = 246) n %	World (N = 20205) n %
INR value, n(%)	n (missing)	3413 (73)	157134 (8319)
	<2	1100 (32.2)	50514 (32.1)
	2-3	1773 (51.9)	81056 (51.6)
	>3	540 (15.8)	25564 (16.3)
INR value	n (missing)	3413 (73)	157134 (8319)
	Mean (SD)	2.4 (0.9)	2.4 (0.9)
	Median (IQR)	2.2 (1.8 to 2.7)	2.3 (1.8 to 2.8)
	Min to Max	0.8 to 11.6	0.8 to 20.0
TTR, n(%)	n (missing)	173 (73)	11485 (8720)
	<65	90 (52.0)	6734 (58.6)
	>=65	83 (48.0)	4751 (41.4)
TTR	n (missing)	173 (73)	11485 (8720)
	Mean (SD)	60.4 (24.7)	55.2 (27.3)
	Median (IQR)	64.2 (46.1 to 77.6)	59.0 (37.0 to 76.1)
	Min to Max	0.0 to 100.0	0.0 to 100.0

## Event rates during the first year of follow-up (rates per 100 person-years)

	Canada		World	
	Events	Rate (95% CI)	Events	Rate (95% CI)
Death	50	6.05 (4.58 to 7.98)	2103	4.38 (4.20 to 4.57)
Cardiovascular Death	15	1.81 (1.09 to 3.01)	789	1.64 (1.53 to 1.76)
Non-cardiovascular death	19	2.30 (1.47 to 3.60)	771	1.61 (1.50 to 1.72)
Undetermined Cause	16	1.94 (1.19 to 3.16)	543	1.13 (1.04 to 1.23)
Stroke/SE	10	1.22 (0.66 to 2.26)	650	1.36 (1.26 to 1.47)
Major Bleeding	10	1.22 (0.65 to 2.26)	407	0.85 (0.77 to 0.94)
Acute coronary syndrome	7	0.85 (0.40 to 1.78)	378	0.79 (0.71 to 0.87)
Congestive hearth failure	33	4.08 (2.90 to 5.74)	1052	2.22 (2.09 to 2.35)



## Cause of death during the first year of follow-up

	Canada		World	
	n	%	n	%
Cardiovascular causes				
Congestive heart failure	8	53.3	262	33.2
Sudden or unwitnessed death	0		127	16.1
Myocardial infarction	2	13.3	89	11.3
Non-haemorrhagic stroke (Ischemic Stroke)	0		86	10.9
Non Cardiovascular causes				
Malignancy	4	21.1	233	30.2
Respiratory failure	6	31.6	142	18.4
Infection	2	10.5	81	10.5
Sepsis	2	10.5	74	9.6

## Type of stroke during the first year of follow-up

	Canada		World	
	n	%	n	%
Stroke (not including systemic embolism)	10	1.12	585	1.12
Primary Ischemic	4	0.45	406	0.78
of which secondary hemorrhagic ischemic			22	0.04
Primary intracerebral hemorrhage	3	0.34	71	0.14
Intracerebral	3	0.34	44	0.08
Intraventricular			9	0.02
Subarachnoid			13	0.02
Undetermined	3	0.34	108	0.21

## Severity of bleeding during the first year of follow-up

Outcome	Canada		World	
	n	%	n	%
Major Bleed	10	0.02	407	0.78
Non-Major Clinically Relevant	18	0.04	645	1.24
Minor	23	0.04	1167	2.24
Unknown	10	0.02	136	0.26